| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction, and binds to HIF-specific DNA sequences, indicating a pro-lymphangiogenic as well as a pro-angiogenic effect in vitro. It inhibits colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway.
|
|---|---|
| ln Vitro |
In vitro, deoxyshikonin shows significant synergic antimicrobial activity against S. pneumoniae (MIC=17 μg/mL) and also shows significantly inhibitory activities against MRSA. It has pro-angiogenic and pro-lymphangiogenic effects. It inhibits colorectal cancer through the PI3K/Akt/mTOR pathway.
|
| ln Vivo |
In vivo, deoxyshikonin has been studied for its potential therapeutic applications in skin regeneration, wound healing, and as an antimicrobial agent. Its anti-tumor activity has been demonstrated in various preclinical models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for deoxyshikonin are not standard. Its effects on HIF-1α and VEGF expression can be assessed using molecular biology techniques such as qRT-PCR and Western blotting. Its antimicrobial activity is assessed using standard susceptibility testing methods.
|
| Cell Assay |
Cell-based assays for deoxyshikonin involve treating cancer cell lines with the compound and measuring cell proliferation, apoptosis, and signaling pathway activation. Its effects on the PI3K/Akt/mTOR pathway are evaluated by measuring the phosphorylation status of key proteins. Its pro-angiogenic effects are assessed in endothelial cell models.
|
| Animal Protocol |
In vivo animal studies for deoxyshikonin are conducted in models of cancer, infection, and wound healing. The compound is administered orally or topically, and its effects on tumor growth, bacterial load, and wound closure are assessed.
|
| ADME/Pharmacokinetics |
Deoxyshikonin has a molecular weight of 272.30 and a molecular formula of C16H16O4. It is soluble in DMSO. For storage, it should be kept at -20°C.
|
| Toxicity/Toxicokinetics |
The toxicological profile of deoxyshikonin has not been extensively characterized. As a natural naphthoquinone, it may have cytotoxic effects at high concentrations. As with any research compound, appropriate safety precautions should be taken when handling it.
|
| References |
|
| Additional Infomation |
Deoxyshikonin is a hydroxy-1,4-naphthoquinone. Deoxyshikonin has been reported in Lithospermum erythrorhizon, Lithospermum verum, and other organisms for which data are available. See also: Lithospermum erythrorhizon root (partial); ...).
Deoxyshikonin is a naphthoquinone compound with antibacterial, antioxidant, anti-inflammatory, and anticancer effects. It is active against MRSA and S. pneumoniae. It promotes angiogenesis and lymphangiogenesis through HIF-1α and VEGF. It is a valuable research tool for studying cancer, angiogenesis, and infectious diseases. |
| Molecular Formula |
C16H16O4
|
|---|---|
| Molecular Weight |
272.2958
|
| Exact Mass |
272.104
|
| CAS # |
43043-74-9
|
| PubChem CID |
98914
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
503.7±50.0 °C at 760 mmHg
|
| Melting Point |
91ºC
|
| Flash Point |
272.5±26.6 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.611
|
| LogP |
4.72
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
471
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VOMDIEGPEURZJO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H16O4/c1-9(2)4-3-5-10-8-13(19)14-11(17)6-7-12(18)15(14)16(10)20/h4,6-8,17-18H,3,5H2,1-2H3
|
| Chemical Name |
5,8-dihydroxy-2-(4-methylpent-3-enyl)naphthalene-1,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~122.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6724 mL | 18.3621 mL | 36.7242 mL | |
| 5 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL | |
| 10 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
